When Sami Said and Viktor Mutt isolated VIP from porcine intestinal extracts in 1970, they named it Vasoactive Intestinal Peptide because it relaxed blood vessels and came from the gut. The name stuck — but it's misleading. VIP is far more than a vasoactive gut peptide. It is one of the most broadly distributed neuropeptides in the human body, with receptors on neurons, immune cells, smooth muscle, airway epithelium, and endocrine glands.¹

VIP is better understood as a pleiotropic signaling molecule — a messenger that carries different instructions depending on which cell type receives it. In neurons, it modulates circadian rhythm and neuroprotection. In immune cells, it suppresses inflammation. In smooth muscle, it causes relaxation. In the GI tract, it regulates secretion and motility.

VIP signals through two G-protein coupled receptors:

VPAC1: Widely distributed — immune cells, brain, liver, lung. Primarily mediates VIP's anti-inflammatory and neuroprotective effects.

VPAC2: More restricted — brain (suprachiasmatic nucleus), smooth muscle, endocrine tissue. Primarily mediates circadian rhythm regulation and smooth muscle relaxation.²

Both receptors couple to the Gαs subunit, activating adenylyl cyclase and raising cAMP. But downstream signaling diverges based on cell type — the same cAMP increase in an immune cell produces anti-inflammatory effects while in a smooth muscle cell it produces relaxation. Context determines function.

VIP's most extensively studied function is immune regulation. In animal models of autoimmune and inflammatory conditions:

• VIP reduced production of pro-inflammatory cytokines (TNF-α, IL-6, IL-12)
• VIP promoted production of anti-inflammatory cytokines (IL-10)
• VIP modulated the Th1/Th2 balance toward anti-inflammatory Th2 responses
• VIP inhibited macrophage activation and reduced nitric oxide production from iNOS³

The anti-inflammatory mechanism is distinct from KPV's NF-κB inhibition. VIP works through VPAC receptor-mediated cAMP signaling. KPV inhibits NF-κB nuclear translocation directly. These are parallel anti-inflammatory pathways — non-overlapping and potentially complementary.

VPAC2 receptors in the suprachiasmatic nucleus (the brain's master clock) implicate VIP in circadian rhythm regulation. VIP-knockout mice show disrupted circadian rhythms and altered sleep-wake cycles. This circadian role connects VIP to the broader biology of how the nervous system coordinates daily physiological cycles.⁴

Neuroprotective effects have been demonstrated in models of brain injury and neurodegeneration, where VIP reduced neuronal death and improved functional outcomes. The mechanism involves both direct neuroprotection (VPAC-mediated survival signaling in neurons) and indirect protection (reduced neuroinflammation).

VIP's greatest research value may be as a neuroimmune tool. It is an endogenous molecule that naturally operates across both the nervous and immune systems — a biological bridge that researchers can use to study how these two systems regulate each other.⁵

Research questions addressable with VIP include: How does neural signaling modulate immune function? Does immune activation affect neural circuit behavior? What molecular mechanisms underlie the clinical observation that stress (neural) worsens inflammatory conditions (immune)?

VIP's broad activity makes it difficult to isolate specific effects. Its short half-life in vivo (minutes) limits its utility in chronic administration studies without delivery modifications. Receptor subtype selectivity between VPAC1 and VPAC2 effects requires careful experimental design.